Results 1 to 10 of about 63,292,925 (286)

Selective IL-23 Inhibition in Conventional Treatment-Refractory Pyoderma Gangrenosum: A Multicenter, Retrospective Study. [PDF]

Int J Dermatol
Bettolini L, Maronese CA, Derlino F, Genovese G, Moltrasio C, Sarno L, Buffon S, Cei B, Granieri G, Dini V, Romanelli M, Maione V, Bighetti S, Venturini M, Cammarata E, Savoia P, Di Guardo A, Gargiulo L, Cascio Ingurgio R, Costanzo A, Burzi L, Leporati C, Di Cristo N, Zerbinati N, Ortega-Loayza AG, Marzano AV.   +25 more
europepmc   +1 more source

IL-23 Inhibitors in Psoriasis: What Have We Learnt so Far? [PDF]

J Inflamm Res
Megna M, D'Agostino M, Feo F, Ventura V, Tommasino N, Potestio L.   +5 more
europepmc   +1 more source

Vitamin D Receptor-Macrophage-IL-23 Axis in Inflammatory Bowel Disease: Pathogenic Mechanisms and Therapeutic Hope. [PDF]

J Clin Med
Grigoraș A, Ghemiș L, Goriuc A, Murariu A, Fiterman N, Jdid N, Blaga T, Foia GL.   +7 more
europepmc   +1 more source

FDA approves Icotyde^TM (Icotrokinra): a novel IL-23 receptor antagonist for plaque psoriasis. [PDF]

Ann Med Surg (Lond)
Abid MA, Abid MH, Hasan AH, Afzal MD.
europepmc   +1 more source

Superior Clinical and Economic Value of IL-23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis. [PDF]

Int J Dermatol
Falco GM, Ippoliti E, Gori N, Caldarola G, De Simone C, Di Giorgi N, Longo PG, Galluzzo M, Bianchi L, Marcelli L, Talamonti M, Cannizzaro MV, Di Nardo L, Peris K.   +13 more
europepmc   +1 more source

Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors. [PDF]

Dermatol Pract Concept
Cammarata E, Airoldi C, Colombo J, Ucciero A, Mastorino L, Arese V, Burzi L, Castelli F, Chiarpenello M, Graziola F, Leporati C, Ortoncelli M, Pella P, Pertusi G, Pisterna A, Quaglino P, Ribero S, Rossotto G, Tiberio R, Dapavo P, Savoia P.   +20 more
europepmc   +1 more source

The IL-23/IL-17 axis in Behçet's syndrome pathogenesis: from immunological perspectives to therapeutic implications. [PDF]

Front Immunol
Naffaa ME, Hassan F, Omar M, Abacar K, McGonagle D.   +4 more
europepmc   +1 more source

Hepatitis B Virus Reactivation Risk With IL-17, IL-23/IL-12, or JAK Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Liver Int
Alhalabi M, Alshiekh HA.
europepmc   +1 more source

Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials. [PDF]

Front Immunol
Xin T, Sun S, Liu Y.
europepmc   +1 more source

A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit. [PDF]

Immunity
Jiang R, Blauvelt A, Shi L, Tsoi LC, Bogle R, Fox J, Gharaee-Kermani M, Chen L, Zhang H, Xing X, Sarkar MK, Plazyo O, Kahlenberg JM, Billi AC, Matheson RT, Photowala H, Ehst BD, Gudjonsson JE.   +17 more
europepmc   +1 more source